[1]DE Rijk M C, Launer L J, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group[J]. Neurology,2000,54(11 Suppl 5):S21-23.
[2] Rajput A H, Birdi S. Epidemiology of Parkinson’s disease[J]. Parkinsonism RelatDisord,1997,3(4):175-186.
[3] Zhang Z X, Roman G C, Hong Z, et al. Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai[J]. Lancet,2005,365(9459):595-597.
[4] Postuma R B, Berg D, Stern M,et al. MDS clinical diagnostic criteria for Parkinson’s disease[J]. Mov Disorder,2015,30(12):1591-1601.
[5] Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity[J]. J Neurosci,2003,23(24):8506-8512.
[6] 沈鸿雁,徐赫男,胡 春.用于帕金森病治疗的单胺氧化酶B抑制剂的临床评述[J].中国药物化学杂志,2011,21(6):483-488.
[7] Chen J J, Swope D M, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s disease[J]. Clin Ther,2007,29(9):1825-1849.
[8] Finberg J P, Gillman K. Selective inhibitors of monoamine oxidase type B and the "cheese effect"[J]. Int Rev Neurobiol,2011,100:169-190.
[9] Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future[J]. TranslNeurodegener, 2015,12(4):3.
[10] Müller T. Pharmacokinetic/pharmacodynamic evaluation of rasagilinemesylate for Parkinson’s disease[J]. Expert Opin Drug MetabToxicol,2014,10(10):1423-1432.
[11] Dr Jark J, Chen Pharm D BCPS CGP, DDM Swope. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease[J]. J Clin Pharmacol,2005,45(8):878-894.
[12] Dimpfel W, Hoffmann J A. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro[J]. BMC Pharmacol,2011,(11):2-7.
[13] McCormack P L. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease[J]. CNS Drugs,2014,28(11):1083-1097.
[14] Siu E C, Tyndale R F. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice[J]. J Pharmacol Exp Ther,2008,324(3):992-999.
[15] OB Am, T Amit, MBH Youdim. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline[J]. NeurosciLett,2004,355(3):169-172.
[16] Hubalek F, Binda C, Li M, et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues[J]. J Med Chem,2004,(47):1760-1766.
[17] Youdim M B, Gross A, Finberg J P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B[J]. Br J Pharmacol,2001,(132):500-506.
[18] Fowler J S, Volkow N D, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal[J]. Synapse,1994,(18):86-93.
[19] Freedman N M, Mishani E, Krausz Y, et al. In Vivo Measurement of Brain Monoamine Oxidase B Occupancy by Rasagiline, Using 11C-L-Deprenyl and PET[J]. J Nucl Med,2005,(46):1618-1624.
[20] Riederer P, Laux G. MAO-inhibitors in Parkinson’s Disease[J]. Exp Neurobiol,2011,20(1):1-17.
[21] Green A R, Mitchell B D, Tordoff A F. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroytryptamine[J]. Br J Pharmacol, 1977,(60):343-349.
[22] Goetz C G, Schwid S R, Eberly S W, et al. Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease[J]. Neurology,2006,66(9):1427-1429.